Summary
Viruses cause significant disease, exemplified by the COVID-19 pandemic. Most studies of virus-host interactions focused on proteins, however, RNA holds great promise for basic and therapeutic exploration. Viruses evolved elaborate strategies for RNA protection, including 5’ capping and internal modification. The goal of this proposal is to discover and characterize viral RNA modifications installed by viral enzymes, including their role in innate immune evasion. This could uncover novel RNA-based mechanisms of viral replication and host modulation and lead to therapeutic targets.
Many viruses encode methyltransferases (MTases) for canonical RNA 5’ capping. Curiously, no cap was identified for hepatitis C virus (HCV), an important human pathogen. We recently found that the cellular metabolite, flavin adenine dinucleotide (FAD), is used as noncanonical initiating nucleotide by the HCV polymerase at high frequency resulting in a 5’FAD cap on HCV RNA. This is the first description of a virus using this cap type for protecting its RNA and, remarkably, the first robust description of FAD capping across any kingdom of life. In Aim 1, we will investigate the functional role of the HCV 5’FAD cap, including viral evasion of innate immune sensing and RNA stability. We will also explore the evolutionary conservation of metabolite capping across RNA viruses and explore its potential as antiviral target.
Viral MTases further perform 2’-O-methylation (2’OMe) of internal RNA residues, a modification that also may protect from innate recognition. In Aim 2, the extent of 2’OMe on viral RNA will be mapped and the individual contribution of 5’ and internal modification to innate immune evasion will be dissected.
In aggregate, these aims will uncover how viral enzymes modify the termini and internal viral RNA residues and associated evasion of innate immunity. The outcome could reshape understanding of viral RNA biology, open novel research directions and lead to antiviral targets.
Many viruses encode methyltransferases (MTases) for canonical RNA 5’ capping. Curiously, no cap was identified for hepatitis C virus (HCV), an important human pathogen. We recently found that the cellular metabolite, flavin adenine dinucleotide (FAD), is used as noncanonical initiating nucleotide by the HCV polymerase at high frequency resulting in a 5’FAD cap on HCV RNA. This is the first description of a virus using this cap type for protecting its RNA and, remarkably, the first robust description of FAD capping across any kingdom of life. In Aim 1, we will investigate the functional role of the HCV 5’FAD cap, including viral evasion of innate immune sensing and RNA stability. We will also explore the evolutionary conservation of metabolite capping across RNA viruses and explore its potential as antiviral target.
Viral MTases further perform 2’-O-methylation (2’OMe) of internal RNA residues, a modification that also may protect from innate recognition. In Aim 2, the extent of 2’OMe on viral RNA will be mapped and the individual contribution of 5’ and internal modification to innate immune evasion will be dissected.
In aggregate, these aims will uncover how viral enzymes modify the termini and internal viral RNA residues and associated evasion of innate immunity. The outcome could reshape understanding of viral RNA biology, open novel research directions and lead to antiviral targets.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101125362 |
| Start date: | 01-07-2024 |
| End date: | 30-06-2029 |
| Total budget - Public funding: | 1 996 986,00 Euro - 1 996 986,00 Euro |
Cordis data
Original description
Viruses cause significant disease, exemplified by the COVID-19 pandemic. Most studies of virus-host interactions focused on proteins, however, RNA holds great promise for basic and therapeutic exploration. Viruses evolved elaborate strategies for RNA protection, including 5’ capping and internal modification. The goal of this proposal is to discover and characterize viral RNA modifications installed by viral enzymes, including their role in innate immune evasion. This could uncover novel RNA-based mechanisms of viral replication and host modulation and lead to therapeutic targets.Many viruses encode methyltransferases (MTases) for canonical RNA 5’ capping. Curiously, no cap was identified for hepatitis C virus (HCV), an important human pathogen. We recently found that the cellular metabolite, flavin adenine dinucleotide (FAD), is used as noncanonical initiating nucleotide by the HCV polymerase at high frequency resulting in a 5’FAD cap on HCV RNA. This is the first description of a virus using this cap type for protecting its RNA and, remarkably, the first robust description of FAD capping across any kingdom of life. In Aim 1, we will investigate the functional role of the HCV 5’FAD cap, including viral evasion of innate immune sensing and RNA stability. We will also explore the evolutionary conservation of metabolite capping across RNA viruses and explore its potential as antiviral target.
Viral MTases further perform 2’-O-methylation (2’OMe) of internal RNA residues, a modification that also may protect from innate recognition. In Aim 2, the extent of 2’OMe on viral RNA will be mapped and the individual contribution of 5’ and internal modification to innate immune evasion will be dissected.
In aggregate, these aims will uncover how viral enzymes modify the termini and internal viral RNA residues and associated evasion of innate immunity. The outcome could reshape understanding of viral RNA biology, open novel research directions and lead to antiviral targets.
Status
SIGNEDCall topic
ERC-2023-COGUpdate Date
12-03-2024
Images
No images available.
Geographical location(s)
